An Early Phase 1 interventional study of 68Ga-PSMA-11 in Prostate Cancer and Positron-Emission Tomography, sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by First Affiliated Hospital of Fujian Medical University · Early Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. gallium 68 PSMA-11 · Prostatic Neoplasms.
Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, this one is the 4th largest by planned enrollment, is one of 9 that started in 2020, is one of 8 in phase 1, reaches primary completion later than 1 of the 10 other live ones, and was the 30th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–90 · Men only
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in China
Ages 18+ · Men only
Peking Union Medical College Hospital · Sites in China
Ages 18–90 · Men only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–80 · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 12
First in 2015; this study’s year is marked. 9 started in 2020.
This study's planned enrollment of 600 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 50 across the 49 interventional studies. Of the 31 that completed or were terminated, 18 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 49 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.
15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University: 10 open now, 13 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 1, reaches primary completion later than 1 of the 12 other live ones, and was the 1st registered.
First Affiliated Hospital of Fujian Medical University’s Prostatic Neoplasms studies by the year they started, since 2020.
3 of the studies testing gallium 68 PSMA-11 in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052214Phase 3Telix Pharmaceuticals (Innovations) Pty LimitedPSMA PET Combined With MRI for the Detection of PCa | 2027-01 |
| NCT05849298Novartis PharmaceuticalsA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | 2026-12-23 |
| NCT07747493University Health Network, Toronto68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among First Affiliated Hospital of Fujian Medical University’s 15 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
To evaluate the potential usefulness of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions, efficacy assessment and recurrence monitoring in various types of cancer.
Subjects with various types of cancer underwent 68Ga-PSMA-11 PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-PSMA-11 PET/CT were calculated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(i) adult population (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled 68Ga-PSMA-11 PET/CT scan; (iv) patients who were able to provide (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
(i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Drug: 68Ga-PSMA-11
Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Also known as: Diagnostic Test: PET/CT scan
Standardized uptake value (SUV)
Standardized uptake value (SUV) of 68Ga-PSMA-11 for each target lesion of subject or suspected primary tumor or/and metastasis.
Time frame: 30 days
Diagnostic efficacy
The sensitivity, specificity and accuracy of 68Ga-PSMA-11 PET/CT were calculated.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Dec 2024, 50 months after the start.
Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 50 months is close to that.
Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gallium 68 PSMA-11
First Affiliated Hospital of Fujian Medical University